Skip to main content
Top
Published in: Diabetologia 4/2010

01-04-2010 | Article

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

Authors: I. Hadjiyanni, K. A. Siminovitch, J. S. Danska, D. J. Drucker

Published in: Diabetologia | Issue 4/2010

Login to get access

Abstract

Aims/hypothesis

Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glucose control in animals and humans with type 1 diabetes. However, there is little information on the role of the GLP-1R in the immune system. We studied the role of the GLP-1R in immune function in wild-type (WT) and non-obese diabetic (NOD) and Glp1r −/− mice.

Methods

Glp1r mRNA expression was examined in sorted immune subpopulations by RT–PCR. The effects of GLP-1R activation were assessed on cAMP production and proliferation, migration and survival of primary immune cells from WT and NOD mice. The ability of primary cells from Glp1r −/− mice to proliferate, migrate or survive apoptosis was determined. Immunophenotyping studies were performed to assess the frequency of immune subpopulations in Glp1r −/− mice.

Results

Ex vivo activation of the GLP-1R resulted in a modest but significant elevation of cAMP in primary thymocytes and splenocytes from both WT and NOD mice. GLP-1R activation did not increase proliferation of primary thymocytes, splenocytes or peripheral lymph node cells. In contrast, Glp1r −/− thymocytes exhibited a hypoproliferative response, whilst peripheral Glp1r −/− lymphocytes were hyperproliferative in response to mitogenic stimulation. Activation or loss of GLP-1R signalling did not modify apoptosis or chemotaxis in primary lymphocytes. Male Glp1r −/− mice exhibited a significantly lower percentage of peripheral regulatory T cells, although no differences were observed in the numbers of CD4+ and CD8+ T cells and B cells in the spleen and lymph nodes of Glp1r −/− mice.

Conclusions/interpretation

These studies establish that GLP-1R signalling may regulate lymphocyte proliferation and maintenance of peripheral regulatory T cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Madsbad S, Krarup T, Deacon CF, Holst JJ (2008) Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 11:491–499CrossRefPubMed Madsbad S, Krarup T, Deacon CF, Holst JJ (2008) Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 11:491–499CrossRefPubMed
2.
go back to reference Dupre J (2005) Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 128:149–157CrossRefPubMed Dupre J (2005) Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 128:149–157CrossRefPubMed
3.
go back to reference Sherry NA, Chen W, Kushner JA et al (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148:5136–5144CrossRefPubMed Sherry NA, Chen W, Kushner JA et al (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148:5136–5144CrossRefPubMed
4.
go back to reference Ogawa N, List JF, Habener JF, Maki T (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700–1705CrossRefPubMed Ogawa N, List JF, Habener JF, Maki T (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700–1705CrossRefPubMed
5.
go back to reference Yang Z, Chen M, Carter JD et al (2006) Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 344:1017–1022CrossRefPubMed Yang Z, Chen M, Carter JD et al (2006) Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 344:1017–1022CrossRefPubMed
6.
go back to reference Tian B, Hao J, Zhang Y et al (2009) Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 87:198–206CrossRefPubMed Tian B, Hao J, Zhang Y et al (2009) Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 87:198–206CrossRefPubMed
7.
go back to reference National Institutes of Health Clinical Center (2009) Effect of AC2993 with or without immunosuppression on beta cell function in patients with type I diabetes. Available from www.clinicaltrials.gov/, accessed 6 September 2009. National Institutes of Health Clinical Center (2009) Effect of AC2993 with or without immunosuppression on beta cell function in patients with type I diabetes. Available from www.​clinicaltrials.​gov/​, accessed 6 September 2009.
8.
go back to reference Toyoda K, Okitsu T, Yamane S et al (2008) GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 367:793–798CrossRefPubMed Toyoda K, Okitsu T, Yamane S et al (2008) GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 367:793–798CrossRefPubMed
9.
go back to reference King A, Lock J, Xu G, Bonner-Weir S, Weir GC (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074–2079CrossRefPubMed King A, Lock J, Xu G, Bonner-Weir S, Weir GC (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074–2079CrossRefPubMed
10.
go back to reference Juang JH, Kuo CH, Wu CH, Juang C (2008) Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets. Cell Transplant 17:641–647CrossRefPubMed Juang JH, Kuo CH, Wu CH, Juang C (2008) Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets. Cell Transplant 17:641–647CrossRefPubMed
11.
go back to reference Zhang J, Tokui Y, Yamagata K et al (2007) Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50:1900–1909CrossRefPubMed Zhang J, Tokui Y, Yamagata K et al (2007) Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50:1900–1909CrossRefPubMed
12.
go back to reference Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ (2008) Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338–1349CrossRefPubMed Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ (2008) Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338–1349CrossRefPubMed
13.
go back to reference Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281–3288CrossRefPubMed Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281–3288CrossRefPubMed
14.
15.
go back to reference Xue S, Wasserfall CH, Parker M et al (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150:152–156CrossRefPubMed Xue S, Wasserfall CH, Parker M et al (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150:152–156CrossRefPubMed
16.
go back to reference Ghofaili KA, Fung M, Ao Z et al (2007) Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 83:24–28CrossRefPubMed Ghofaili KA, Fung M, Ao Z et al (2007) Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 83:24–28CrossRefPubMed
17.
go back to reference Froud T, Faradji RN, Pileggi A et al (2008) The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 86:36–45CrossRefPubMed Froud T, Faradji RN, Pileggi A et al (2008) The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 86:36–45CrossRefPubMed
18.
go back to reference Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S (2005) Impaired post-thymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol 174:4081–4089PubMed Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S (2005) Impaired post-thymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol 174:4081–4089PubMed
19.
go back to reference Vielkind S, Gallagher-Gambarelli M, Gomez M, Hinton HJ, Cantrell DA (2005) Integrin regulation by RhoA in thymocytes. J Immunol 175:350–357PubMed Vielkind S, Gallagher-Gambarelli M, Gomez M, Hinton HJ, Cantrell DA (2005) Integrin regulation by RhoA in thymocytes. J Immunol 175:350–357PubMed
20.
go back to reference Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336CrossRefPubMed Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336CrossRefPubMed
21.
go back to reference Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546–593CrossRefPubMed Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546–593CrossRefPubMed
22.
go back to reference Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262–269CrossRefPubMed Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262–269CrossRefPubMed
23.
go back to reference Morran MP, Omenn GS, Pietropaolo M (2008) Immunology and genetics of type 1 diabetes. Mt Sinai J Med 75:314–327CrossRefPubMed Morran MP, Omenn GS, Pietropaolo M (2008) Immunology and genetics of type 1 diabetes. Mt Sinai J Med 75:314–327CrossRefPubMed
24.
go back to reference Tisch R, Wang B (2008) Dysregulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol 100:125–149CrossRefPubMed Tisch R, Wang B (2008) Dysregulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol 100:125–149CrossRefPubMed
25.
go back to reference Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113CrossRefPubMed Donath MY, Ehses JA, Maedler K et al (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54(Suppl 2):S108–S113CrossRefPubMed
26.
go back to reference Ehses JA, Boni-Schnetzler M, Faulenbach M, Donath MY (2008) Macrophages, cytokines and beta-cell death in Type 2 diabetes. Biochem Soc Trans 36:340–342CrossRefPubMed Ehses JA, Boni-Schnetzler M, Faulenbach M, Donath MY (2008) Macrophages, cytokines and beta-cell death in Type 2 diabetes. Biochem Soc Trans 36:340–342CrossRefPubMed
27.
go back to reference Guest CB, Park MJ, Johnson DR, Freund GG (2008) The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 13:5187–5194CrossRefPubMed Guest CB, Park MJ, Johnson DR, Freund GG (2008) The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 13:5187–5194CrossRefPubMed
28.
go back to reference Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434–3438CrossRefPubMed Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434–3438CrossRefPubMed
29.
go back to reference Campos RV, Lee YC, Drucker DJ (1994) Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156–2164CrossRefPubMed Campos RV, Lee YC, Drucker DJ (1994) Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156–2164CrossRefPubMed
30.
go back to reference Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978CrossRefPubMed Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978CrossRefPubMed
31.
go back to reference Chiu PP, Jevnikar AM, Danska JS (2001) Genetic control of T and B lymphocyte activation in nonobese diabetic mice. J Immunol 167:7169–7179PubMed Chiu PP, Jevnikar AM, Danska JS (2001) Genetic control of T and B lymphocyte activation in nonobese diabetic mice. J Immunol 167:7169–7179PubMed
32.
go back to reference Ivakine EA, Fox CJ, Paterson AD et al (2005) Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse. J Immunol 174:7129–7140PubMed Ivakine EA, Fox CJ, Paterson AD et al (2005) Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse. J Immunol 174:7129–7140PubMed
33.
go back to reference Sgouroudis E, Piccirillo CA (2009) Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 25:208–218CrossRefPubMed Sgouroudis E, Piccirillo CA (2009) Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 25:208–218CrossRefPubMed
34.
go back to reference Sojka DK, Huang YH, Fowell DJ (2008) Mechanisms of regulatory T cell suppression: a diverse arsenal for a moving target. Immunology 124:13–22CrossRefPubMed Sojka DK, Huang YH, Fowell DJ (2008) Mechanisms of regulatory T cell suppression: a diverse arsenal for a moving target. Immunology 124:13–22CrossRefPubMed
35.
go back to reference Vendetti S, Patrizio M, Riccomi A, de Magistris MT (2006) Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP. J Leukoc Biol 80:880–888CrossRefPubMed Vendetti S, Patrizio M, Riccomi A, de Magistris MT (2006) Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP. J Leukoc Biol 80:880–888CrossRefPubMed
36.
go back to reference Wang T, Sheppard JR, Foker JE (1978) Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis. Science 201:155–157CrossRefPubMed Wang T, Sheppard JR, Foker JE (1978) Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis. Science 201:155–157CrossRefPubMed
37.
go back to reference Takigawa M, Waksman BH (1981) Mechanisms of lymphocyte ‘deletion’ by high concentrations of ligand. I. Cyclic AMP levels and cell death in T-lymphocytes exposed to high concentrations of concanavalin A. Cell Immunol 58:29–38CrossRefPubMed Takigawa M, Waksman BH (1981) Mechanisms of lymphocyte ‘deletion’ by high concentrations of ligand. I. Cyclic AMP levels and cell death in T-lymphocytes exposed to high concentrations of concanavalin A. Cell Immunol 58:29–38CrossRefPubMed
38.
go back to reference Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM (1985) Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313:318–320CrossRefPubMed Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM (1985) Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313:318–320CrossRefPubMed
39.
go back to reference Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806–815CrossRefPubMed Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806–815CrossRefPubMed
40.
go back to reference Susini S, Roche E, Prentki M, Schlegel W (1998) Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J 12:1173–1182PubMed Susini S, Roche E, Prentki M, Schlegel W (1998) Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J 12:1173–1182PubMed
41.
go back to reference Lawrence MC, Bhatt HS, Easom RA (2002) NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 51:691–698CrossRefPubMed Lawrence MC, Bhatt HS, Easom RA (2002) NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 51:691–698CrossRefPubMed
42.
go back to reference Song J, Lei FT, Xiong X, Haque R (2008) Intracellular signals of T cell costimulation. Cell Mol Immunol 5:239–247CrossRefPubMed Song J, Lei FT, Xiong X, Haque R (2008) Intracellular signals of T cell costimulation. Cell Mol Immunol 5:239–247CrossRefPubMed
43.
go back to reference Flamez D, Gilon P, Moens K et al (1999) Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48:1979–1986CrossRefPubMed Flamez D, Gilon P, Moens K et al (1999) Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48:1979–1986CrossRefPubMed
44.
45.
go back to reference Pederson RA, Satkunarajah M, McIntosh CH et al (1998) Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor −/− mice. Diabetes 47:1046–1052CrossRefPubMed Pederson RA, Satkunarajah M, McIntosh CH et al (1998) Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor −/− mice. Diabetes 47:1046–1052CrossRefPubMed
46.
go back to reference Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471–478CrossRefPubMed Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471–478CrossRefPubMed
47.
go back to reference Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983CrossRefPubMed Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983CrossRefPubMed
48.
go back to reference Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302:881–888CrossRefPubMed Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302:881–888CrossRefPubMed
49.
go back to reference Cinalli RM, Herman CE, Lew BO, Wieman HL, Thompson CB, Rathmell JC (2005) T cell homeostasis requires G protein-coupled receptor-mediated access to trophic signals that promote growth and inhibit chemotaxis. Eur J Immunol 35:786–795CrossRefPubMed Cinalli RM, Herman CE, Lew BO, Wieman HL, Thompson CB, Rathmell JC (2005) T cell homeostasis requires G protein-coupled receptor-mediated access to trophic signals that promote growth and inhibit chemotaxis. Eur J Immunol 35:786–795CrossRefPubMed
50.
51.
go back to reference Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U (2001) Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta 1546:79–86PubMed Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U (2001) Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta 1546:79–86PubMed
52.
go back to reference Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641–651CrossRefPubMed Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T cell modulation. Diabetes 58:641–651CrossRefPubMed
Metadata
Title
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
Authors
I. Hadjiyanni
K. A. Siminovitch
J. S. Danska
D. J. Drucker
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1643-x

Other articles of this Issue 4/2010

Diabetologia 4/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.